WO2020032904A2 - Traitement du cancer par vaccin par culture et immunisation simultanées de cellules nk autologues (cellules tueuses naturelles) avec des cellules cancéreuses autologues - Google Patents

Traitement du cancer par vaccin par culture et immunisation simultanées de cellules nk autologues (cellules tueuses naturelles) avec des cellules cancéreuses autologues Download PDF

Info

Publication number
WO2020032904A2
WO2020032904A2 PCT/TR2019/050669 TR2019050669W WO2020032904A2 WO 2020032904 A2 WO2020032904 A2 WO 2020032904A2 TR 2019050669 W TR2019050669 W TR 2019050669W WO 2020032904 A2 WO2020032904 A2 WO 2020032904A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
autologous
cancer
vaccine
treatment method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050669
Other languages
English (en)
Other versions
WO2020032904A9 (fr
Inventor
Serdar Baki ALBAYRAK
Ayhan OLCAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innowayrg Arastirma Gelistirme Ve Danismanlik Hizmetleri Sanayi Ve Ticaret AS
TC Istanbul Aydin University
Original Assignee
Innowayrg Arastirma Gelistirme Ve Danismanlik Hizmetleri Sanayi Ve Ticaret AS
TC Istanbul Aydin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innowayrg Arastirma Gelistirme Ve Danismanlik Hizmetleri Sanayi Ve Ticaret AS, TC Istanbul Aydin University filed Critical Innowayrg Arastirma Gelistirme Ve Danismanlik Hizmetleri Sanayi Ve Ticaret AS
Publication of WO2020032904A2 publication Critical patent/WO2020032904A2/fr
Publication of WO2020032904A9 publication Critical patent/WO2020032904A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Definitions

  • the invention relates to the use of cancer vaccine treatment by synchronously culturing and immunizing of autologous nk (natural killer) cells with autologous cancer cells with the aim of preventing recurrence and definitive treatment in GBM and anaplastic astrocytoma and in the treatment of certain Grade 2 astrocytomas.
  • GBM Glioblastoma multiforme
  • the immune suppressor cells Treg and M2 and tumor-dependent macrophages are drawn into the medium suppresses effector T cells.
  • Said invention in EP 2 341 927 B1 relates to peptides, nucleic acids and cells used in immunotherapeutic methods.
  • the invention relates to cancer immunotherapy.
  • the invention also relates to tumor-associated cytotoxic T cell (CTC) peptide epitopes that are used as active pharmaceutical ingredients of vaccine compositions that promote anti-tumor immune responses in combination with or alone with other tumor-associated peptides.
  • CTC cytotoxic T cell
  • the existing invention relates to 30 peptide sequences and their variants derived from human tumor cell molecules of HLA Class I and Class II that can be used in vaccine compositions to generate anti tumor immune responses. It is a peptide-based vaccine for the treatment of GBM and other cancers and a tumor-associated peptide composition.
  • the invention described above belongs to the peptide-based cancer vaccine group in the prior art.
  • the present invention relates to the cancer vaccine treatment by synchronously culturing and immunizing of autologous nk (natural killer) cells with autologous cancer cells developed to eliminate the above-mentioned disadvantages and bring new advantages to the relevant field.
  • the vaccine of the invention is based on the principle of specifically “immunizing" the patient's Natural Killer (NK) cells in co-cell culture as a whole with GBM cells and reintroducing them to the patient.
  • NK Natural Killer
  • Gliomir Cancer tissue samples of human brain cancers (GBM, anaplastic astrocytoma, medulloblastoma, pineoblastoma etc. and some grade 2 astrocytomas) and other human organ cancers (lung, prostate, melanoma, breast, pancreas, stomach, colon, others) obtained by surgery and the cell culture of the Natural Killer lymphocyte group (NK) synchronously isolated from the peripheral venous blood (NK) will be co-cultured with the cancer cells for 2 weeks to 2 months and thus the NK cells cells will be immunized against the tumor cells.
  • GBM Human brain cancers
  • NK Natural Killer lymphocyte group
  • NK Natural Killer lymphocyte group
  • NK cells will be isolated from tumor cells using appropriate assays and, if ethical committee approval is obtained, patients may be given subcutaneously, subcutaneously, intravenously / intraarterially (intraarticularly) or intracavitaryly. This procedure can be repeated several times if necessary using immunized autologous NKs stored and cell passages, and the healing of patients will be monitored clinically and radiologically.
  • Gliovac Radiation-inactivated autologous-GBM cells and three different allogeneic GBM cell groups are combined with GM-CSF and priorly low-dose cyclophosphamide treatment is given.
  • Schijns et al. tested the vaccine in 9 relapsed GBM patients; In this group, 40-week survival is (77%) - in the group without GlioVac is (10%).
  • EGFRvlll vaccine practice generated against human cytomegalovirus (CMV) -derived antigens, IDH-1 (R132H), IL13Ra2, HER-2, gp100, TRP2, EphA2, survivin, WT1 , SOX2, SOX11 , MAGE-A1.MAGE-A3, AIM2, SART1 antigens:
  • CMV cytomegalovirus
  • IDH1 isocitrate dehydrogenase-1
  • R132H is another tumor-specific antigen vaccine
  • Phase 1 tumor-specific antigen vaccine
  • Peptide vaccines-Rindopepimut (Celldex Therapeutics): It is the most advanced peptide vaccine which consists of synthetically obtained, mutated epidermal growth factor receptor (EGFRIII) antigen with the combination of "Keyhole limpet hemocyanin" as carrier protein and co-administration with GM-SCF and which Phase 1 , 2 and 3 trials still in progress.
  • EGFRvlM is present in approximately 30% of GBM patients and forms a target for the vaccine by forming a neo-antigenic junction not found in normal cells after deletion.
  • rindopepimut Flumoral and cellular immune responses are triggered, and in the ongoing Phase 2 trial, rindopepimut is combined with bevacizumab. Recently, in a controlled study, the rindopepimut group showed a 2-month difference in survival after relapse compared to the placebo group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Le glioblastome multiforme (GBM) et l'astrocytome de type anaplasique sont les tumeurs cérébrales astrocytiques les plus malignes et communes, avec une incidence de 5/100,000 et des types pro-neuronal, neuronal, classique, mésenchymateux. Il n'y a pas de traitement définitif et l'espérance de vie moyenne est de 45-71 semaines. La période de récurrence est d'environ 9-36 semaines, et la résection chirurgicale radicale, la radiochimiothérapie (témozolomide, 6-12 cycles) est la qualité des soins, générant une perte fonctionnelle et structurale minimale; en cas de récurrence, une nouvelle chirurgie et un traitement de bévacizumab sont effectués dans les cas appropriés. Le vaccin proposé vise la prévention de toute récurrence et le traitement définitif dans le traitement du GBM et de l'astrocytome anaplasique et dans le traitement de certains degrés 2 d'astrocytomes. Quoi qu'il en soit, cette approche peut être appliquée à tous les cancers solides humains.
PCT/TR2019/050669 2018-08-10 2019-08-08 Traitement du cancer par vaccin par culture et immunisation simultanées de cellules nk autologues (cellules tueuses naturelles) avec des cellules cancéreuses autologues Ceased WO2020032904A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/11683 2018-08-10
TR2018/11683A TR201811683A2 (tr) 2018-08-10 2018-08-10 OTOLOG NK (Natural Killer) HÜCRELERİNİN OTOLOG KANSER HÜCRELERİYLE EŞ ZAMANLI KÜLTÜRE EDİLİP İMMUNİZE EDİLMESİ İLE KANSER AŞI TEDAVİSİ

Publications (2)

Publication Number Publication Date
WO2020032904A2 true WO2020032904A2 (fr) 2020-02-13
WO2020032904A9 WO2020032904A9 (fr) 2020-05-14

Family

ID=67001284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050669 Ceased WO2020032904A2 (fr) 2018-08-10 2019-08-08 Traitement du cancer par vaccin par culture et immunisation simultanées de cellules nk autologues (cellules tueuses naturelles) avec des cellules cancéreuses autologues

Country Status (2)

Country Link
TR (1) TR201811683A2 (fr)
WO (1) WO2020032904A2 (fr)

Also Published As

Publication number Publication date
TR201811683A2 (tr) 2018-09-21
WO2020032904A9 (fr) 2020-05-14

Similar Documents

Publication Publication Date Title
Vicari et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
Bernatchez et al. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy
US9238064B2 (en) Allogeneic cancer cell-based immunotherapy
ES2965957T3 (es) Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer
Dominguez et al. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses
AU2015233542B2 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
US20100303868A1 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2014161887A1 (fr) Thérapie immunitaire anticancéreuse ciblée
Kjaergaard et al. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine
JP2021038225A (ja) ネコ用がんワクチン
AU2006312013B2 (en) Concurrent chemotherapy and immunotherapy
RU2627175C2 (ru) Новый пептид, имеющий 5 соединенных эпитопов ctl
Har-Noy et al. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma
Locy et al. Dendritic cells: the tools for cancer treatment
WO2020032904A2 (fr) Traitement du cancer par vaccin par culture et immunisation simultanées de cellules nk autologues (cellules tueuses naturelles) avec des cellules cancéreuses autologues
US20170021002A1 (en) Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors
WO2018058490A1 (fr) Polypeptide antigène tumoral dérivé de col14a1 et son utilisation
Caproni et al. Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles. Cancers 2023, 15, 3328
Albert et al. Immunotherapy for Sarcoma
KR100530576B1 (ko) 수지상세포를 이용한 암 면역 치료방법
HK40113603A (zh) 蛋白质抗原及其用途
Veiga et al. Lymphocytes transfectes pour therapie antitumorale
Salem et al. Tumours: Immunotherapy
HK1136486A (en) Concurrent chemotherapy and immunotherapy
TW201707715A (zh) 用於治療ｈｅｒ－２陽性癌症之組合免疫療法及放射線療法

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19848669

Country of ref document: EP

Kind code of ref document: A2